Huntington’s Disease Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 21.00 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Huntington's Disease Treatment Market Analysis
Huntington's disease treatment market is projected to register a CAGR of 21% during the forecast period.
COVID-19 had a significant impact on the growth of the market. According to the European Huntington Association data updated in May 2021, patients with Huntington's disease (HD) do not necessarily have a higher risk of getting COVID-19 due to the disease itself. However, patients with symptomatic Huntington's disease may have a higher chance of getting pneumonia since they are more likely to be bedridden and malnourished. HD patients could be more susceptible to symptoms if exposed to COVID-19 and have more major diseases. As a result, there was a strong demand for effective treatment of the target disease during the pandemic since people with Huntington's disease were at risk of contracting COVID-19 infection. The COVID-19 pandemic has subsided globally. Thus, the market is anticipated to experience stagnant growth during the forecast period.
Factors such as the global prevalence of Huntington's disease are expected to drive the target market's growth. As per the article published in the Journal of Neuroepidemiology in November 2021, the prevalence of Huntington's disease was around 10 cases per 100,000 people annually, with a higher prevalence in North America, Northwestern Europe, the Middle East, and Australia. In the regions mentioned above, the estimated range of Huntington's disease is between 5.96 and 13.70 cases per 100,000 people. As per the same source, in Asia, the prevalence is estimated to be 0.41-0.70 cases per 100,000 people annually. As Huntington's disease becomes more common, the need for effective treatments is anticipated to increase, fueling the market's growth throughout the forecast period.
Increasing R&D activities and product development are also expected to contribute to the market's growth over the forecast period. For instance, in April 2021, Voyager Therapeutics Inc. received the US FDA clearance for an IND application for its VY-HTT, a gene therapy candidate designed to treat Huntington's disease. The therapy is designed to reduce the expression of the huntingtin gene to alter the disease progression further. Similarly, in December 2021, uniQure NV presented clinical outcomes for the first four patients enrolled in the lower-dose cohort of its ongoing Phase I/II clinical trial of AMT-130. AMT-130 is a gene therapy program designed to treat Huntington's disease.
However, the high cost of developing effective treatment is expected to hamper the market's growth over the forecast period.
Huntington's Disease Treatment Market Trends
Symptomatic Treatment Segment is Expected to Hold a Major Market Share Over the Forecast Period
Symptomatic therapeutic development majorly focuses on motor impairment and chorea. Chorea remains the most prominent clinical feature of Huntington's disease, for which most therapeutic studies have been conducted. Relatively high availability and usage rates of symptom management therapeutics are expected to account for a significant share during the forecast period. The rising need for multiple treatments and the intervention of a multispecialty care team for symptomatic management resulting in additional expenses may contribute to the development of the segment over the forecast period.
Key factors such as rising awareness campaigns and increasing product developments by various market players are expected to contribute to the growth of the segment. For instance, in November 2022, Neurocrine Biosciences Inc. reported additional findings from the Phase 3 KINECT-HD study investigating Valbenazine for treating chorea associated with Huntington's Disease (HD). According to the company, Valbenazine showed a statistically significant improvement over the placebo in the Total Maximal Chorea (TMC) score. In September 2022, Teva Pharmaceutical launched the Honestly HD website to help people better understand what to expect from Huntington's Disease (HD) chorea, one of HD's most apparent and curable symptoms, and how to communicate to their doctor about maintaining independence. Therefore, continuous R&D activities and awareness programs by key players are expected to create lucrative opportunities for the segment during the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a significant market share over the forecast period due to the rising incidence of Huntington's disease, the presence of key players, and growing R&D funding by the government. According to data published by Cleveland Clinic in January 2021, Huntington's disease affects about 30,000 Americans annually. The report also mentioned that the disease prevalence in North America was 5.7 per 100,000 people annually. As Huntington's condition becomes more prevalent in this region, demand for efficient treatments is anticipated to rise, driving the growth of the target market throughout the forecast period.
Increasing product development and R&D activities by companies are expected to fuel the market's growth over the forecast period. For instance, in April 2022, PTC Therapeutics launched a Phase 2 trial evaluating PTC518, an investigational treatment for Huntington's disease in the United States. The PIVOT-HD trial, which is split into two parts, will be conducted at clinical facilities worldwide. Before being monitored for 12 weeks, participants will be randomly assigned to either a placebo or PTC518 (approximately three months). The pharmacology and pharmacodynamic effect of PTC518-the interactions between the body and a particular compound-will be evaluated in this first section. The second phase will involve a nine-month follow-up period during which researchers will evaluate PTC518's effects on disease biomarkers. In September 2021, Sage Therapeutics Inc. received fast-track designation by the Food and Drug Administration (FDA) for SAGE-718, a potential HD therapy. In June 2021, Galyan Bio planned to commence a clinical trial in collaboration with Bicoll GmbH for its small molecules candidate that aimed at slowing the progression of Huntington's disease.
As a result, the rising prevalence of the target disease, increased R&D, and supportive regulatory authorities are anticipated to contribute to the market expansion in this region throughout the projection period.
Huntington's Disease Treatment Industry Overview
The Huntington's disease treatment market is currently fragmented with several large, small, and medium-sized players. Some of the companies currently dominating the market are Pfizer Inc., Alnylam Pharmaceuticals Inc., Ceregene Inc., Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd, Ionis Pharmaceuticals, Neurocrine Biosciences Inc., Prilenia Therapeutics, Azevan Pharmaceuticals, and Lundbeck.
Huntington's Disease Treatment Market Leaders
Pfizer, Inc.
Alnylam Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
Neurocrine Biosciences, Inc.
Ionis Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
Huntington's Disease Treatment Market News
- In July 2022, UniQure announced 12-month data on safety and Huntington lowering from the first cohort of 10 people with the disease to undergo surgery. The company is working on an experimental drug for Huntington's disease called AMY-130, which is delivered via brain surgery.
- In January 2022, Ionis Pharmaceuticals Inc. announced a partnership with Roche for the evaluation of Tominersen in a new Phase 2 trial for the treatment of Huntington's disease.
Huntingtons Disease Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Huntington's Disease in Developed Countries
4.2.2 Robust Funding for Research on Huntington's Disease
4.3 Market Restraints
4.3.1 High Cost for the Development of Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type
5.1.1 Symptomatic Treatment
5.1.2 Disease-modifying Therapies
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Alnylam Pharmaceuticals Inc.
6.1.3 Ceregene Inc.
6.1.4 Prana Biotechnology Limited
6.1.5 Teva Pharmaceutical Industries Ltd
6.1.6 Ionis Pharmaceuticals
6.1.7 Neurocrine Biosciences Inc.
6.1.8 Prilenia Therapeutics
6.1.9 Azevan Pharmaceuticals
6.1.10 Lundbeck
6.1.11 PTC Therapeutics
6.1.12 UniQure
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Huntington's Disease Treatment Industry Segmentation
As per the scope of this report, Huntington's disease treatment covers various treatment modalities commercially available. It is a genetic disorder that mostly occurs at the age of 30-50, leading to the degeneration of nerve cells in the brain.
The Huntington's disease treatment market is segmented by type (symptomatic treatment and disease-modifying therapies), end user (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values in (in USD million) for the above segments.
| By Type | |
| Symptomatic Treatment | |
| Disease-modifying Therapies |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Online Pharmacies |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Huntingtons Disease Treatment Market Research FAQs
What is the current Huntington�s Disease Treatment Market size?
The Huntington�s Disease Treatment Market is projected to register a CAGR of 21% during the forecast period (2024-2029)
Who are the key players in Huntington�s Disease Treatment Market?
Pfizer, Inc., Alnylam Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Neurocrine Biosciences, Inc. and Ionis Pharmaceuticals are the major companies operating in the Huntington�s Disease Treatment Market.
Which is the fastest growing region in Huntington�s Disease Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Huntington�s Disease Treatment Market?
In 2024, the North America accounts for the largest market share in Huntington�s Disease Treatment Market.
What years does this Huntington�s Disease Treatment Market cover?
The report covers the Huntington�s Disease Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Huntington�s Disease Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Huntington’s Disease Treatment Industry Report
Statistics for the 2024 Huntington’s Disease Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Huntington’s Disease Treatment analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
